Bonesupport Holding AB (publ) announced the publication of mid- to long-term data confirming the sustained clinical effectiveness of CERAMENT G in a single-stage protocol to manage chronic osteomyelitis. The study followed 100 patients treated at the Nuffield Orthopaedic Centre, Oxford University Hospitals. Results at a mean follow-up of 6.05 years [range: 4.2 to 8.4 years] were reported: 94% of patients remained infection-free; 3% fracture rate and no further pathologic fractures beyond the first year after surgery.

The study was published in the September issue of The Bone and Joint Journal. The long-term results will be presented, and has been selected as one of the ten best papers, at this year's annual meeting of the European Bone and Joint Infection Society (EBJIS) held in Graz, Austria on 8-10 September. Approximately 500 surgeons are expected to attend.

CERAMENT G is implanted to promote bone healing in bone voids or defects and simultaneously to protect it from infection. More than 70,000 patients have been treated thus far using the CERAMENT bone healing technology.